@article{oai:kanazawa-u.repo.nii.ac.jp:00014319,
 author = {Mizukoshi, Eishiro and Kaneko, Shuichi},
 journal = {Inflammation and Immunity in Cancer},
 month = {Jan},
 note = {Hepatocellular carcinoma (HCC) is the sixth most common type of cancer globally. Although many different kinds of treatment are performed for HCC according to the practical guidelines, the prognosis of patients is not still satisfactory because the effects of treatments are limited for advanced tumors and the recurrence rate of HCC, even in early stages, is very high. Therefore, immunotherapy is highly anticipated as a new treatment method for HCC. For the development of a new HCC therapy, we attempted to establish immunotherapy using dendritic cells (DCs) and peptide vaccine. In several clinical trials that we performed, we confirmed that the immunotherapy was safe and well-tolerated by HCC patients. We observed that DC therapy prolonged the recurrence-free survival of patients compared with that of patients without DC infusion, as well as observing the radiological anti-tumor effect in HCC patients with peptide vaccine. In this chapter, we summarize the results of previous studies using DC and peptide vaccine, including our own data, and describe the prospects of immunotherapy for HCC. © 2015, Springer Japan. All rights reserved., [Book Chapter]},
 pages = {123--132},
 title = {Development of immunotherapy for hepatocellular carcinoma},
 year = {2015}
}